Nervous System Symptoms Associated With COVID 19 : NS-COV
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 99
- 试验地点
- 1
- 主要终点
- percentage of patients in the Neuro + and Neuro- groups
研究概览
简要总结
This study aim to prospectively evaluate the neuropsychiatric symptoms of patients infected with the SARS-CoV-2 virus by a standardized neuropsychiatric examination : the global CASE scale (Clinical Assessment Scale in Autoimmune Encephalitis), and the prevalence of disturbances of consciousness, focal neurological deficit, cognitive impairment, headache, anosmia, sleep disturbances, impaired autonomic nervous system and peritraumatic stress.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Being hospitalized at the Toulouse University Hospital for a COVID-19 infection proven by a probable PCR or COVID-type examination on the chest scan
- •Have given oral consent for the collection of clinical neurological data
- •Be in a clinical state compatible with a 30-minute neurological examination
- •Be French-speaking
- •Be affiliated to a Social Security scheme
排除标准
- •Refusal of the neurological examination
- •History of neurological pathology at a severe stage
- •Pregnant or breastfeeding woman
- •Persons with tutors or curators
结局指标
主要结局
percentage of patients in the Neuro + and Neuro- groups
时间窗: Baseline T0 : inclusion visit
The percentage is deducted from the score on a global scale by the Clinical Assessment Scale in Autoimmune Between 0 and 1, patients will be classified in the Neuro group, if this score is greater than or equal to 2, patients will be classified in the Neuro + group.
次要结局
未报告次要终点